DNA damage accumulation and repair defects in FLT3-ITD acute myeloid leukemia: Implications for clonal evolution and disease progression

被引:12
作者
Lagunas-Rangel, Francisco Alejandro [1 ]
机构
[1] Uppsala Univ, Dept Surg Sci, BMC Box 593,Husargatan 3, S-75124 Uppsala, Sweden
关键词
AML; FLT3; inhibitor; homologous recombination; NHEJ; poor clinical prognosis; ROS; INTERNAL TANDEM DUPLICATIONS; WORLD-HEALTH-ORGANIZATION; CONFER RESISTANCE; MUTATIONS; CANCER; ROS; CLASSIFICATION; ACTIVATION; INHIBITORS; EXPRESSION;
D O I
10.1002/hon.3076
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Acute myeloid leukemia is a group of hematological diseases that have a high mortality rate. During the development of this pathology, hematopoietic cells acquire chromosomal rearrangements and multiple genetic mutations, including FLT3-ITD. FLT3-ITD is a marker associated with a poor clinical prognosis and involves the activation of pathways such as PI3K/AKT, MAPK/ERK, and JAK/STAT that favor the survival and proliferation of leukemic cells. In addition, FLT3-ITD leads to overproduction of reactive oxygen species and defective DNA damage repair, both implicated in the appearance of new mutations and leukemic clones. Thus, the purpose of this review is to illustrate the molecular mechanisms through which FLT3-ITD generates genetic instability and how it facilitates clonal evolution with the generation of more resistant and aggressive cells. Likewise, this article discusses the feasibility of combined therapies with FLT3 inhibitors and inhibitors of DNA repair pathways.
引用
收藏
页码:26 / 38
页数:13
相关论文
共 75 条
  • [1] The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib
    Albers, C.
    Leischner, H.
    Verbeek, M.
    Yu, C.
    Illert, A. L.
    Peschel, C.
    von Bubnoff, N.
    Duyster, J.
    [J]. LEUKEMIA, 2013, 27 (06) : 1416 - 1418
  • [2] FLT3-ITD and its current role in acute myeloid leukaemia
    Alejandro Lagunas-Rangel, Francisco
    Chavez-Valencia, Venice
    [J]. MEDICAL ONCOLOGY, 2017, 34 (06)
  • [3] A new perspective on oxidation of DNA repair proteins and cancer
    Alnajjar, Khadijeh S.
    Sweasy, Joann B.
    [J]. DNA REPAIR, 2019, 76 : 60 - 69
  • [4] The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
    Arber, Daniel A.
    Orazi, Attilio
    Hasserjian, Robert
    Thiele, Jurgen
    Borowitz, Michael J.
    Le Beau, Michelle M.
    Bloomfield, Clara D.
    Cazzola, Mario
    Vardiman, James W.
    [J]. BLOOD, 2016, 127 (20) : 2391 - 2405
  • [5] FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L)
    Bagrintseva, K
    Geisenhof, S
    Kern, R
    Eichenlaub, S
    Reindl, C
    Ellwart, JW
    Hiddemann, W
    Spiekermann, K
    [J]. BLOOD, 2005, 105 (09) : 3679 - 3685
  • [6] The NOX family of ROS-generating NADPH oxidases: Physiology and pathophysiology
    Bedard, Karen
    Krause, Karl-Heinz
    [J]. PHYSIOLOGICAL REVIEWS, 2007, 87 (01) : 245 - 313
  • [7] Genetic and non-genetic clonal diversity in cancer evolution
    Black, James R. M.
    McGranahan, Nicholas
    [J]. NATURE REVIEWS CANCER, 2021, 21 (06) : 379 - 392
  • [8] Modulation of FLT3 signal transduction through cytoplasmic cysteine residues indicates the potential for redox regulation
    Boehmer, Annette
    Barz, Saskia
    Schwab, Katjana
    Kolbe, Ulrike
    Gabel, Anke
    Kirkpatrick, Joanna
    Ohlenschlaeger, Oliver
    Goerlach, Matthias
    Boehmer, Frank-D.
    [J]. REDOX BIOLOGY, 2020, 28
  • [9] Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies
    Bowman, Robert L.
    Busque, Lambert
    Levine, Ross L.
    [J]. CELL STEM CELL, 2018, 22 (02) : 157 - 170
  • [10] Hypertranscription and replication stress in cancer
    Bowry, Akhil
    Kelly, Richard D. W.
    Petermann, Eva
    [J]. TRENDS IN CANCER, 2021, 7 (09): : 863 - 877